Literature DB >> 25122884

Synaptic GluN2A and GluN2B containing NMDA receptors within the superficial dorsal horn activated following primary afferent stimulation.

Chi-Kun Tong1, Amy B MacDermott2.   

Abstract

NMDA receptors are important elements in pain signaling in the spinal cord dorsal horn. They are heterotetramers, typically composed of two GluN1 and two of four GluN2 subunits: GluN2A-2D. Mice lacking some of the GluN2 subunits show deficits in pain transmission yet functional synaptic localization of these receptor subtypes in the dorsal horn has not been fully resolved. In this study, we have investigated the composition of synaptic NMDA receptors expressed in monosynaptic and polysynaptic pathways from peripheral sensory fibers to lamina I neurons in rats. We focused on substance P receptor-expressing (NK1R+) projection neurons, critical for expression of hyperalgesia and allodynia. EAB-318 and (R)-CPP, GluN2A/B antagonists, blocked both monosynaptic and polysynaptic NMDA EPSCs initiated by primary afferent activation by ∼90%. Physiological measurements exploiting the voltage dependence of monosynaptic EPSCs similarly indicated dominant expression of GluN2A/B types of synaptic NMDA receptors. In addition, at synapses between C fibers and NK1R+ neurons, NMDA receptor activation initiated a secondary, depolarizing current. Ifenprodil, a GluN2B antagonist, caused modest suppression of monosynaptic NMDA EPSC amplitudes, but had a widely variable, sometimes powerful, effect on polysynaptic responses following primary afferent stimulation when inhibitory inputs were blocked to mimic neuropathic pain. We conclude that GluN2B subunits are moderately expressed at primary afferent synapses on lamina I NK1R+ neurons, but play more important roles for polysynaptic NMDA EPSCs driven by primary afferents following disinhibition, supporting the view that the analgesic effect of the GluN2B antagonist on neuropathic pain is at least in part, within the spinal cord.
Copyright © 2014 the authors 0270-6474/14/3410808-13$15.00/0.

Entities:  

Keywords:  NK1 receptor; disinhibition; ifenprodil; polysynaptic; spinal cord

Mesh:

Substances:

Year:  2014        PMID: 25122884      PMCID: PMC4131007          DOI: 10.1523/JNEUROSCI.0145-14.2014

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  62 in total

1.  Spinal lamina I neurons that express neurokinin 1 receptors: morphological analysis.

Authors:  O Cheunsuang; R Morris
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

2.  Alteration in synaptic inputs through C-afferent fibers to substantia gelatinosa neurons of the rat spinal dorsal horn during postnatal development.

Authors:  T Nakatsuka; T Ataka; E Kumamoto; T Tamaki; M Yoshimura
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

3.  Modulation of triheteromeric NMDA receptors by N-terminal domain ligands.

Authors:  Christopher J Hatton; Pierre Paoletti
Journal:  Neuron       Date:  2005-04-21       Impact factor: 17.173

Review 4.  N-methyl-D-aspartic acid receptor structure and function.

Authors:  C J McBain; M L Mayer
Journal:  Physiol Rev       Date:  1994-07       Impact factor: 37.312

5.  NMDA receptor-mediated currents in rat cerebellar granule and unipolar brush cells.

Authors:  Daniela Billups; Ying-Bing Liu; Susanne Birnstiel; N Traverse Slater
Journal:  J Neurophysiol       Date:  2002-04       Impact factor: 2.714

6.  A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones.

Authors:  J N Kew; G Trube; J A Kemp
Journal:  J Physiol       Date:  1996-12-15       Impact factor: 5.182

7.  Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist CP-101,606 in a rat chronic constriction injury model.

Authors:  Etsuko Nakazato; Aki Kato; Shuzo Watanabe
Journal:  Pharmacology       Date:  2004-09-27       Impact factor: 2.547

8.  Disinhibition opens the gate to pathological pain signaling in superficial neurokinin 1 receptor-expressing neurons in rat spinal cord.

Authors:  Carole Torsney; Amy B MacDermott
Journal:  J Neurosci       Date:  2006-02-08       Impact factor: 6.167

9.  Neurokinin receptor 1-expressing spinal cord neurons in lamina I and III/IV of postnatal rats receive inputs from capsaicin sensitive fibers.

Authors:  Charalampos Labrakakis; Amy B MacDermott
Journal:  Neurosci Lett       Date:  2003-12-04       Impact factor: 3.046

10.  Synaptic NMDA receptor-dependent Ca²⁺ entry drives membrane potential and Ca²⁺ oscillations in spinal ventral horn neurons.

Authors:  Michael H Alpert; Simon Alford
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

View more
  13 in total

1.  Inhibition Mediated by Glycinergic and GABAergic Receptors on Excitatory Neurons in Mouse Superficial Dorsal Horn Is Location-Specific but Modified by Inflammation.

Authors:  Tomonori Takazawa; Papiya Choudhury; Chi-Kun Tong; Charles M Conway; Grégory Scherrer; Pamela D Flood; Jun Mukai; Amy B MacDermott
Journal:  J Neurosci       Date:  2017-01-27       Impact factor: 6.167

2.  CaMKII binding to GluN2B at S1303 has no role in acute or inflammatory pain.

Authors:  Uche P Maduka; Stephanie R White; Mei-Ling A Joiner; Johannes W Hell; Donna L Hammond
Journal:  Brain Res       Date:  2020-10-14       Impact factor: 3.252

3.  In vivo activation of the SK channel in the spinal cord reduces the NMDA receptor antagonist dose needed to produce antinociception in an inflammatory pain model.

Authors:  Lucia Hipólito; Amanda K Fakira; David Cabañero; Rebecca Blandón; Susan M Carlton; Jose A Morón; Zara Melyan
Journal:  Pain       Date:  2015-05       Impact factor: 7.926

4.  β-arrestin-2 regulates NMDA receptor function in spinal lamina II neurons and duration of persistent pain.

Authors:  Gang Chen; Rou-Gang Xie; Yong-Jing Gao; Zhen-Zhong Xu; Lin-Xia Zhao; Sangsu Bang; Temugin Berta; Chul-Kyu Park; Mark Lay; Wei Chen; Ru-Rong Ji
Journal:  Nat Commun       Date:  2016-08-19       Impact factor: 14.919

5.  NMDA Receptor Activation Underlies the Loss of Spinal Dorsal Horn Neurons and the Transition to Persistent Pain after Peripheral Nerve Injury.

Authors:  Perrine Inquimbert; Martin Moll; Alban Latremoliere; Chi-Kun Tong; John Whang; Gregory F Sheehan; Brendan M Smith; Erica Korb; Maria C P Athié; Olusegun Babaniyi; Nader Ghasemlou; Yuchio Yanagawa; C David Allis; Patrick R Hof; Joachim Scholz
Journal:  Cell Rep       Date:  2018-05-29       Impact factor: 9.423

6.  Conserved contributions of NMDA receptor subtypes to synaptic responses in lamina II spinal neurons across early postnatal development.

Authors:  Hadir Mahmoud; Newton Martin; Michael E Hildebrand
Journal:  Mol Brain       Date:  2020-03-05       Impact factor: 4.041

Review 7.  Qualitative review on N-methyl-D-aspartate receptor expression in rat spinal cord during the postnatal development: Implications for central sensitization and pain.

Authors:  Thomas J de Geus; Jacob Patijn; Elbert A J Joosten
Journal:  Dev Neurobiol       Date:  2020-11-20       Impact factor: 3.964

8.  Hunting for origins of migraine pain: cluster analysis of spontaneous and capsaicin-induced firing in meningeal trigeminal nerve fibers.

Authors:  A Zakharov; C Vitale; E Kilinc; K Koroleva; D Fayuk; I Shelukhina; N Naumenko; A Skorinkin; R Khazipov; R Giniatullin
Journal:  Front Cell Neurosci       Date:  2015-07-28       Impact factor: 5.505

9.  Effects of intrathecal bupivacaine on the NR2B/CaMKIIα/CREB signaling pathway in the rat lumbar spinal cord.

Authors:  Liyan Zhao; Yonghai Zhang; Fan Yang; Di Zhu; Ningkang Li; Li Zhao; Na Li; Jianqiang Yu; Hanxiang Ma
Journal:  Mol Med Rep       Date:  2018-01-17       Impact factor: 2.952

10.  Propofol produces preventive analgesia via GluN2B-containing NMDA Receptor/ERK1/2 Signaling Pathway in a rat model of inflammatory pain.

Authors:  Qiu Qiu; Liting Sun; Xiao-Min Wang; Amy C Y Lo; Kar Lok Wong; Pan Gu; Sau Ching Stanley Wong; Chi Wai Cheung
Journal:  Mol Pain       Date:  2017 Jan-Dec       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.